Pharmagenesis Inc. Receives Funding From New Investors
Natco Pharma Ltd的加拿大子公司以800万美元收购了eGenesis Inc.的4000万股股份,eGenesis Inc.是一家专门从事异种移植的生物技术公司。eGenesis专注于开发安全有效的人体相容器官进行移植。该公司的基因组工程和生产平台通过基因工程独特地解决了跨物种分子不相容性和病毒风险。eGenesis正在推进肾脏,急性肝衰竭和心脏移植...
Cardiac troponin-I (cTnI), as the most valuable and reliable clinically used biomarker, was measured. cTnI was determined with a biochemical analyzer (Triage® Cardiac Panel, Alere San Diego, Inc. CA, USA). Histopathology/Histomorphometry. At the completion of the protocol, irreversible myocardia...
PHARMAGENESIS APPROVED TO SELL FERIDEX IN CHINAReports on the approval received by Pharmagenesis Inc. from the Chinese State Drug Administration to market and sell Feridex, a magnetic resonance imaging contrast agent designed for the early detection of liver lesions, in China....
PHARMAGENESIS JOINT VENTURE TO MAKE/SELL PG2 IN CHINADeals with the joint venture forged by Pharmagenesis Inc. in Palo Alto, California, with Tianjin Zhong Xin Pharmaceutical Group company in China to manufacture and market the cancer therapy drug PG2 developed by Pharmagenesis in China....